Lasers Med Sci:剥脱性和非剥脱性激光都可有效改善萎缩性痤疮瘢痕

2022-05-21 sunshine MedSci原创

寻常痤疮是一种慢性顽固的皮肤炎症,在青少年甚至成年人中的发病率很高。痤疮疤痕是一种常见的美容并发症,可能会给患者带来生理和心理压力,影响患者的生活质量。

寻常痤疮是一种慢性顽固的皮肤炎症,在青少年甚至成年人中的发病率很高。痤疮疤痕是一种常见的美容并发症,可能会给患者带来生理和心理压力,影响患者的生活质量。研究显示,点阵激光被广泛用于改善痤疮,根据波长的不同,FLs可分为点阵烧蚀性激光器(FALs)和点阵非烧蚀性激光器(FNALs)。近日,发表于Lasers Med Sci的一项随机对照试验比较了点阵非剥脱性1927纳米铥激光(FTL)和点阵烧蚀性2940纳米Er:YAG激光(FEL)在治疗痤疮瘢痕方面的疗效和安全性。

研究纳入患有中度或重度萎缩性面部痤疮疤痕的受试者,其左侧面部接受3次FTL治疗,右侧面部接受3次FEL治疗,平均间隔时间为4-6周。最后一次治疗后进行为期12周的随访。主要评估包括Goodman&Baron全球瘢痕定量分级系统(GBS)、自评改善和满意度评分。

 

结果,共有27名受试者完成了研究;FTL侧的平均GBS从基线时的11.15±5.04降至7.07±4.87,改善率为36.54%;FEL侧的平均GBS从10.81±4.46降至7.00±4.07,改善率为35.27%。不良反应包括一过性疼痛、红斑、水肿和痤疮的发生率增加。两种激光器之间没有发现明显差异。

综上所述,该研究结果表明,FTL和FEL都能改善萎缩性痤疮瘢痕,而且耐受性良好。但是,激光治疗期间痤疮的发生可能对激光的疗效产生负面影响。因此,在激光治疗期间,要重视预防寻常痤疮的复发和感染

 

原始出处:

 

Kune Lu, Suiqing Cai. Efficacy and safety comparison between 1927 nm thulium laser and 2940 nm Er:YAG laser in the treatment of facial atrophic acne scarring: a prospective, simultaneous spilt-face clinical trial. Lasers Med Sci. 2022 Apr;37(3):2025-2031. doi: 10.1007/s10103-021-03465-0. 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1942324, encodeId=e7af1942324f5, content=<a href='/topic/show?id=6b418809e8c' target=_blank style='color:#2F92EE;'>#萎缩性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88097, encryptionId=6b418809e8c, topicName=萎缩性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Feb 07 14:51:49 CST 2023, time=2023-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878515, encodeId=e8c118e851504, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Wed Feb 08 15:51:49 CST 2023, time=2023-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696051, encodeId=6f6d169605145, content=<a href='/topic/show?id=03b98809697' target=_blank style='color:#2F92EE;'>#萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88096, encryptionId=03b98809697, topicName=萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53fc29868494, createdName=chendoc252, createdTime=Thu Mar 02 03:51:49 CST 2023, time=2023-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279821, encodeId=b18c12e982143, content=<a href='/topic/show?id=265c66e50ea' target=_blank style='color:#2F92EE;'>#激光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66750, encryptionId=265c66e50ea, topicName=激光)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Tue May 17 13:51:49 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337008, encodeId=3855133e0089b, content=<a href='/topic/show?id=48f8e12220f' target=_blank style='color:#2F92EE;'>#瘢痕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71222, encryptionId=48f8e12220f, topicName=瘢痕)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Tue May 17 13:51:49 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611601, encodeId=4317161160127, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue May 17 13:51:49 CST 2022, time=2022-05-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1942324, encodeId=e7af1942324f5, content=<a href='/topic/show?id=6b418809e8c' target=_blank style='color:#2F92EE;'>#萎缩性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88097, encryptionId=6b418809e8c, topicName=萎缩性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Feb 07 14:51:49 CST 2023, time=2023-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878515, encodeId=e8c118e851504, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Wed Feb 08 15:51:49 CST 2023, time=2023-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696051, encodeId=6f6d169605145, content=<a href='/topic/show?id=03b98809697' target=_blank style='color:#2F92EE;'>#萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88096, encryptionId=03b98809697, topicName=萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53fc29868494, createdName=chendoc252, createdTime=Thu Mar 02 03:51:49 CST 2023, time=2023-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279821, encodeId=b18c12e982143, content=<a href='/topic/show?id=265c66e50ea' target=_blank style='color:#2F92EE;'>#激光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66750, encryptionId=265c66e50ea, topicName=激光)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Tue May 17 13:51:49 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337008, encodeId=3855133e0089b, content=<a href='/topic/show?id=48f8e12220f' target=_blank style='color:#2F92EE;'>#瘢痕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71222, encryptionId=48f8e12220f, topicName=瘢痕)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Tue May 17 13:51:49 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611601, encodeId=4317161160127, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue May 17 13:51:49 CST 2022, time=2022-05-17, status=1, ipAttribution=)]
    2023-02-08 anminleiryan
  3. [GetPortalCommentsPageByObjectIdResponse(id=1942324, encodeId=e7af1942324f5, content=<a href='/topic/show?id=6b418809e8c' target=_blank style='color:#2F92EE;'>#萎缩性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88097, encryptionId=6b418809e8c, topicName=萎缩性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Feb 07 14:51:49 CST 2023, time=2023-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878515, encodeId=e8c118e851504, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Wed Feb 08 15:51:49 CST 2023, time=2023-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696051, encodeId=6f6d169605145, content=<a href='/topic/show?id=03b98809697' target=_blank style='color:#2F92EE;'>#萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88096, encryptionId=03b98809697, topicName=萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53fc29868494, createdName=chendoc252, createdTime=Thu Mar 02 03:51:49 CST 2023, time=2023-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279821, encodeId=b18c12e982143, content=<a href='/topic/show?id=265c66e50ea' target=_blank style='color:#2F92EE;'>#激光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66750, encryptionId=265c66e50ea, topicName=激光)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Tue May 17 13:51:49 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337008, encodeId=3855133e0089b, content=<a href='/topic/show?id=48f8e12220f' target=_blank style='color:#2F92EE;'>#瘢痕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71222, encryptionId=48f8e12220f, topicName=瘢痕)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Tue May 17 13:51:49 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611601, encodeId=4317161160127, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue May 17 13:51:49 CST 2022, time=2022-05-17, status=1, ipAttribution=)]
    2023-03-02 chendoc252
  4. [GetPortalCommentsPageByObjectIdResponse(id=1942324, encodeId=e7af1942324f5, content=<a href='/topic/show?id=6b418809e8c' target=_blank style='color:#2F92EE;'>#萎缩性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88097, encryptionId=6b418809e8c, topicName=萎缩性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Feb 07 14:51:49 CST 2023, time=2023-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878515, encodeId=e8c118e851504, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Wed Feb 08 15:51:49 CST 2023, time=2023-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696051, encodeId=6f6d169605145, content=<a href='/topic/show?id=03b98809697' target=_blank style='color:#2F92EE;'>#萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88096, encryptionId=03b98809697, topicName=萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53fc29868494, createdName=chendoc252, createdTime=Thu Mar 02 03:51:49 CST 2023, time=2023-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279821, encodeId=b18c12e982143, content=<a href='/topic/show?id=265c66e50ea' target=_blank style='color:#2F92EE;'>#激光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66750, encryptionId=265c66e50ea, topicName=激光)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Tue May 17 13:51:49 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337008, encodeId=3855133e0089b, content=<a href='/topic/show?id=48f8e12220f' target=_blank style='color:#2F92EE;'>#瘢痕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71222, encryptionId=48f8e12220f, topicName=瘢痕)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Tue May 17 13:51:49 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611601, encodeId=4317161160127, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue May 17 13:51:49 CST 2022, time=2022-05-17, status=1, ipAttribution=)]
    2022-05-17 oliver169
  5. [GetPortalCommentsPageByObjectIdResponse(id=1942324, encodeId=e7af1942324f5, content=<a href='/topic/show?id=6b418809e8c' target=_blank style='color:#2F92EE;'>#萎缩性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88097, encryptionId=6b418809e8c, topicName=萎缩性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Feb 07 14:51:49 CST 2023, time=2023-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878515, encodeId=e8c118e851504, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Wed Feb 08 15:51:49 CST 2023, time=2023-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696051, encodeId=6f6d169605145, content=<a href='/topic/show?id=03b98809697' target=_blank style='color:#2F92EE;'>#萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88096, encryptionId=03b98809697, topicName=萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53fc29868494, createdName=chendoc252, createdTime=Thu Mar 02 03:51:49 CST 2023, time=2023-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279821, encodeId=b18c12e982143, content=<a href='/topic/show?id=265c66e50ea' target=_blank style='color:#2F92EE;'>#激光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66750, encryptionId=265c66e50ea, topicName=激光)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Tue May 17 13:51:49 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337008, encodeId=3855133e0089b, content=<a href='/topic/show?id=48f8e12220f' target=_blank style='color:#2F92EE;'>#瘢痕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71222, encryptionId=48f8e12220f, topicName=瘢痕)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Tue May 17 13:51:49 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611601, encodeId=4317161160127, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue May 17 13:51:49 CST 2022, time=2022-05-17, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1942324, encodeId=e7af1942324f5, content=<a href='/topic/show?id=6b418809e8c' target=_blank style='color:#2F92EE;'>#萎缩性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88097, encryptionId=6b418809e8c, topicName=萎缩性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Feb 07 14:51:49 CST 2023, time=2023-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878515, encodeId=e8c118e851504, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Wed Feb 08 15:51:49 CST 2023, time=2023-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696051, encodeId=6f6d169605145, content=<a href='/topic/show?id=03b98809697' target=_blank style='color:#2F92EE;'>#萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88096, encryptionId=03b98809697, topicName=萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53fc29868494, createdName=chendoc252, createdTime=Thu Mar 02 03:51:49 CST 2023, time=2023-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279821, encodeId=b18c12e982143, content=<a href='/topic/show?id=265c66e50ea' target=_blank style='color:#2F92EE;'>#激光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66750, encryptionId=265c66e50ea, topicName=激光)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Tue May 17 13:51:49 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337008, encodeId=3855133e0089b, content=<a href='/topic/show?id=48f8e12220f' target=_blank style='color:#2F92EE;'>#瘢痕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71222, encryptionId=48f8e12220f, topicName=瘢痕)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Tue May 17 13:51:49 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611601, encodeId=4317161160127, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue May 17 13:51:49 CST 2022, time=2022-05-17, status=1, ipAttribution=)]

相关资讯

二氧化碳激光点阵激光治疗红色杜洛克猪模型中厚层皮肤移植物挛缩的有效性和安全性

二氧化碳点阵激光在分层植皮后的疤痕管理中发挥着重要作用,它可以松解植皮挛缩,恢复表面的光滑度。

Orthopedics:切口愈合瘢痕更小,外观更好,可以选择皮肤粘结胶带

皮肤粘结胶带通常用于促进皮肤伤口的闭合和轻微裂伤。最近,组织粘合剂,如2-氰基丙烯酸辛酯,因其高抗拉强度,具有抑菌特性和,并可自发脱落而备受欢迎。

肉毒素竟然可以预防面部瘢痕形成

研究表明肉毒素在治疗增生性瘢痕和瘢痕疙瘩方面比皮损内皮质类固醇或安慰剂更有效,经肉毒素治疗的瘢痕在黑色素沉着、瘢痕高度、血管性、柔韧性和瘢痕宽度方面有统计学意义的改善。

Laryngoscope:甲状腺术后的疤痕管理策略,哪项更优?

甲状腺术后的疤痕位于高度敏感和可见的解剖位置,其对外观的影响已成为患者术后满意度的最重要因素之一。近日,发表于Laryngoscope的一项目前瞻性随机试验比较了应用不同方案时的疤痕质量,并最终旨在找

Photodermatol Photoimmunol Photomed:血浆凝胶联合点阵式二氧化碳激光可有效治疗痤疮所致的瘢痕

寻常性痤疮所致的萎缩性痤疮后瘢痕往往永久且难治疗的。萎缩性痤疮后瘢痕的发病率高,对生活质量影响很大,对皮肤科医生来说也是一个治疗上的挑战。

Aesthet Surg J:面部手术后立即长期使用组织胶水可有效减小疤痕体积

手术后疤痕的形成,尤其是疤痕外观的美容问题,是患者和临床医生关注的地方,大大影响病人的满意度。然而,可靠的皮肤支持方案是有限的。